Immunogenic response of different antigenic values: investigation of intradermal purified Vero cell rabies vaccine in healthy volunteers

Immunogenic response of different antigenic values: investigation of intradermal purified Vero cell rabies vaccine in healthy volunteers)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20190314002

Enrollment

Unknown

Registered

2019-03-14

Start date

2019-06-03

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunogenic response of different antigenic values intradermal purified Vero cell rabies vaccine immunogenic response different antigenic values rabies vaccine healthy volunteer intradermal purified Vero cell rabies vaccine

Interventions

The rabies vaccine dilute with 0.5 mL diluent&#44

Intradermal Injection&#44

0.1 ml&#44

2 positions,The rabies vaccine dilute with 1.0 mL diluent&#44

2 positions,The rabies vaccine dilute with 2.0 mL diluent&#44

Intramuscular Injection&#44

1.0 ml&#44

1 position

Active Comparator Biological/Vaccine,Active Comparator Biological/Vaccine,Active Comparator Biological/Vaccine,Active Comparator Biological/Vaccine

Rabies vaccine 0.5 mL,Rabies vaccine 1.0 mL,Rabies vaccine 2.0 mL,Control Group

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Healthy volunteers Male or female, age 18 years or over, but not more than 50 years old 2. Ability to read and sign the patient information sheet and inform consent form

Exclusion criteria

Exclusion criteria: 1. Refuse to sign the patient information sheet and inform consent form. 2. Being a volunteer in another clinical research or having participated in other investigational product research within 4 weeks before entering a clinical trial or being in the equivalent period of 5 times the half-life for another investigational product. 3. Administration of full course of vaccine or at least 3 shots of rabies vaccine before or after contacting the disease. 4. Have a history of allergy to vaccine components in this study. 5. Used to receive serum from horses (such as antiseptic serum, tetanus, serum, rabies, diphtheria, etc.) 6. Have serious illnesses that are dangerous or may cause a risk of participating in a clinical trial. 7. Acquiring Corticosteroids, chloroquine or immunosuppressants or having a history of immunodeficiency. 8. History of drug addiction or alcoholism. 9. Pregnant or breastfeeding females.

Design outcomes

Primary

Measure	Time frame
Immunogenic response of different antigenic values 180 days after administration STATA, One-way ANOVA and two-sample independent t-test	—

Secondary

Measure	Time frame
Side effect of rabies vaccines in subjects who received different antigenic values Throughout the period of the study STATA, One-way ANOVA and two-sample independent t-test	—

Countries

Thailand

Contacts

Public ContactAssist.Prof. Jatuporn Sirikun

Faculty of Medicine, Siriraj Hospital, Mahidol University

j_sirikun@hotmail.com02-419-7727

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026